Mike Huckman

Longtime CNBC biotech reporter, Mike Huckman, is leaving the CNBC family today. Huckman has had a nice run over the last ten years at CNBC. Mike has broken many stories while covering the pharma beat and he has been the go to guy for interviews with biotech CEOs. Prior to working at CNBC, Mike...

Mike Huckman talked on CNBC's Fast Money about three new pills that may be coming to the market to help Americans in the fight against obesity. Three biotech companies have filed for an FDA approval for individual prescription diet drugs. Orexigen Therapeutics, Inc. (NASDAQ: OREX) is one of the...

CNBC's pharmaceuticals reporter Mike Huckman spoke on the Fast Money show about once-a-week diabetes drug called Byetta, that is waiting for FDA approval. The decision will be made on Friday, and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), Eli Lilly & Co. (NYSE: LLY) and Alkermes, Inc. (NASDAQ...

CNBC's Pharmaceuticals Reporter Mike Huckman is speculating about a possible acquisition by Pfizer Inc. (NYSE: PFE). He points out that Lipitor, a drug that is used for lowering blood cholesterol, is the most important drug for Pfizer (PFE). This drug is going generic next year and Pfizer (PFE)...

Biopharma is considered to be a clean industry and the provider of high-end jobs. No wonder, all US cities and states want biopharma. According to CNBC’s Mike Huckman, California has its fair share of biopharma industry, but its base is eroding. California hosts major biotech firms such as Amgen (...

Three out of four prescriptions in the U.S. are filled by generics. CNBC's Mike Huckman reports that Caylon Securities has conducted a poll regarding the use of generic drugs. The study has come up with some interesting facts. According to the report, 65% of the pharmacists expressed their...

A new survey conducted by research firm HCD Research claims that 72 percent of smokers found the word “sucks” appropriate or more than appropriate for Glaxo’s (NYSE: GSK) Nicorrette ad campaign. Talking with CNBC’s Mike Huckman, HCD Research’s Glenn Kessler said that although GSK is one of its...

Merck (NYSE: MRK) stock has been doing well recently. However, all is not well with the Pharma giant. According to CNBC correspondent Mike Huckman, Merck is now moving towards becoming more transparent. Merck recently acquired Schering-Plough. In a surprising move, officials at Merck gave a no-go...

Biotech firm Human Genome Sciences (NASDAQ: HGSI) saw a huge run up in its stock price in Year 2009. Its stock rose by 1447% during the last 52 weeks. The firm is looking forward to an equally promising Year 2010. Speaking with CNBC’s Mike Huckman, Human Genome CEO Tom Watkins said that the firm...

The market is abuzz with rumors that billionaire investor Carl Icahn may launch a proxy battle at Genzyme Corp. (NASDAQ: GENZ). Following the buzz, Genzyme stock rose by 4.41% on Wednesday. While talking with CNBC's Mike Huckman on June 4, 2009, Carl Icahn stated, "...I do believe that the future...